Johnson & Johnson Neil Davie, Ph.D. Head, Late Development Cardiovascular, Metabolism & Pulmonary Hypertension Ruxandra Draghia-Akli, M.D., Ph.D. Global Head Johnson & Johnson Global Public Health R&D Janssen Research & Development Penny Heaton, M.D. ...
“Legend is an innovative biotech company that has developed a differentiated CAR-T therapy, which has shown promising results in early-stage multiple myeloma trials conducted in China. We are excited to bring Janssen’s global...
Janssen Biotech (NYSE:JNJ +0.5%) submits a supplemental New Drug Application (sNDA) seeking clearance for the use of IMBRUVICA (ibrutinib) for the...
Janssen Biotech, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commerci...